Tibulizumab
Modify Date: 2024-01-20 18:07:37
Tibulizumab structure
|
Common Name | Tibulizumab | ||
|---|---|---|---|---|
| CAS Number | 1849636-24-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TibulizumabTibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research[1]. |
| Name | Tibulizumab |
|---|
| Description | Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research[1]. |
|---|---|
| Related Catalog | |
| Target |
IL-17A:14 pM (Kd) BAFF:60 pM (Kd) |
| In Vitro | Tibulizumab (LY 3090106) 与小鼠 BAFF 结合，KD 为 340 nM，但不与小鼠 IL-17 结合。Tibulizumab 与猕猴 BAFF 和猕猴 IL-17 结合，KD 分别为 26.8 pM 和 19 pM[1]。 在 HT-29 细胞中，Tibulizumab 以浓度依赖性方式拮抗 IL-17 诱导的 CXCL1 分泌 (IC50 为 2.00 nM)。在 T1165 细胞中，Tibulizumab 以浓度依赖性方式阻断 BAFF 诱导的增殖 (IC50 为 0.064 nM)。Tibulizumab 同时结合并阻断 BAFF 和 IL-17[1]。 |
| In Vivo | Tibulizumab（LY 3090106；660 µg/小鼠，i.p；66 µg/小鼠，s.c）在小鼠体内有效拮抗人 BAFF 和 IL-17 诱导的生物学效应[1]。 在食蟹猴中，Tibulizumab（i.v，0.3、1、5 或 20 mg/kg；或 s.c，5 mg/kg）抑制 B 细胞发育和存活，并在循环中保持功能完整，并延长半衰期 [1]。 |
| References |
| No Any Chemical & Physical Properties |